P2X receptor signaling in skeletal muscle health and disease

Wiley Interdisciplinary Reviews: Membrane Transport and Signaling

Volumn 2, Issue 6, 2013, Pages 265-274

  Young, Christopher N J ^a   Sinadinos, Anthony ^a   Gorecki, Dariusz C ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DIALDEHYDE; PURINERGIC P2X RECEPTOR; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X2 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X6 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; SURAMIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL INFILTRATION; CELL PROLIFERATION; CELL REGENERATION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; MUSCLE FUNCTION; MUSCLE INJURY; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION;

EID: 84886439542     PISSN: 2190460X     EISSN: 21904618     Source Type: Journal    
DOI: 10.1002/wmts.96     Document Type: Article

References (82)

1. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961, 9:493-495.
2. Mok GF, Sweetman D. Many routes to the same destination: lessons from skeletal muscle development. Reproduction 2011, 141:301-312.
3. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Andrade FH. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001, 98:12062-12067.
4. Swaggart KA, Heydemann A, Palmer AA, McNally EM. Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics 2011, 43:24-31.
5. Davies NW. Modulation of ATP-sensitive K+ channels in skeletal muscle by intracellular protons. Nature 1990, 343:375-377.
6. Hetherington HP, Spencer DD, Vaughan JT, Pan JW. Quantitative (31)P spectroscopic imaging of human brain at 4 Tesla: assessment of gray and white matter differences of phosphocreatine and ATP. Magn Reson Med 2001, 45:46-52.
7. Kushmerick MJ, Moerland TS, Wiseman RW. Mammalian skeletal muscle fibers distinguished by contents of phosphocreatine, ATP, and Pi. Proc Natl Acad Sci USA 1992, 89:7521-7525.
8. Becq F. CFTR channels and adenosine triphosphate release: the impossible rendez-vous revisited in skeletal muscle. J Physiol 2010, 588:4605-4606.
9. Novak I. ATP as a signaling molecule: the exocrine focus. News Physiol Sci 2003, 18:12-17.
10. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, Hoogsteden HC, Luttmann W, Ferrari D, Di Virgilio F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007, 13:913-919.
11. Martinon F. Detection of immune danger signals by NALP3. J Leukoc Biol 2008, 83:507-511.
12. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007, 64:1471-1483.
13. Kaczmarek-Hájek K, Lörinczi E, Hausmann R, Nicke A. Molecular and functional properties of P2X receptors--recent progress and persisting challenges. Purinergic Signal 2012, 8:375-417.
14. Kolb HA, Wakelam MJ. Transmitter-like action of ATP on patched membranes of cultured myoblasts and myotubes. Nature 1983, 303:621-623.
15. Deli T, Toth BI, Czifra G, Szappanos H, Biro T, Csernoch L. Differences in purinergic and voltage-dependent signalling during protein kinase Calpha overexpression- and culturing-induced differentiation of C2C12 myoblasts. J Muscle Res Cell Motil 2006, 27:617-630.
16. Deli T, Szappanos H, Szigeti GP, Cseri J, Kovács L, Csernoch L. Contribution from P2X and P2Y purinoreceptors to ATP-evoked changes in intracellular calcium concentration on cultured myotubes. Pflugers Arch 2007, 453:519-529.
17. Ryten M, Hoebertz A, Burnstock G. Sequential expression of three receptor subtypes for extracellular ATP in developing rat skeletal muscle. Dev Dyn 2001, 221:331-341.
18. Bornø A, Ploug T, Bune LT, Rosenmeier JB, Thaning P. Purinergic receptors expressed in human skeletal muscle fibres. Purinergic Signal 2012, 8:255-264.
19. Choi RC, Man ML, Ling KK, Ip NY, Simon J, Barnard EA, Tsim KW. Expression of the P2Y1 nucleotide receptor in chick muscle: its functional role in the regulation of acetylcholinesterase and acetylcholine receptor. J Neurosci 2001, 21:9224-9234.
20. Henning RH. Purinoceptors in neuromuscular transmission. Pharmacol Ther 1997, 74:115-128.
21. Buvinic S, Almarza G, Bustamante M, Casas M, Lopez J, Riquelme M, Saez JC, Huidobro-Toro JP, Jaimovich E. ATP released by electrical stimuli elicits calcium transients and gene expression in skeletal muscle. J Biol Chem 2009, 284:34490-34505.
22. Banachewicz W, Suplat D, Krzemiński P, Pomorski P, Barańska J. P2 nucleotide receptors on C2C12 satellite cells. Purinergic Signal 2005, 1:249-257.
23. Martinello T, Baldoin MC, Morbiato L, Paganin M, Tarricone E, Schiavo G, Bianchini E, Sandona D, Betto R. Extracellular ATP signaling during differentiation of C2C12 skeletal muscle cells: role in proliferation. Mol Cell Biochem 2011, 351:183-196.
24. Meyer MP, Groschel-Stewart U, Robson T, Burnstock G. Expression of two ATP-gated ion channels, P2X5 and P2X6, in developing chick skeletal muscle. Dev Dyn 1999, 216:442-449.
25. Ryten M, Dunn PM, Neary JT, Burnstock G. ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. J Cell Biol 2002, 158:345-355.
26. Tsim KW, Barnard EA. The signaling pathways mediated by P2Y nucleotide receptors in the formation and maintenance of the skeletal neuromuscular junction. Neurosignals 2002, 11:58-64.
27. Tung EK, Choi RC, Siow NL, Jiang JX, Ling KK, Simon J, Barnard EA, Tsim KW. P2Y2 receptor activation regulates the expression of acetylcholinesterase and acetylcholine receptor genes at vertebrate neuromuscular junctions. Mol Pharmacol 2004, 66:794-806.
28. Ryten M, Koshi R, Knight GE, Turmaine M, Dunn P, Cockayne DA, Ford AP, Burnstock G. Abnormalities in neuromuscular junction structure and skeletal muscle function in mice lacking the P2X2 nucleotide receptor. Neuroscience 2007, 148:700-711.
29. Jiang T, Yeung D, Lien CF, Gorecki DC. Localized expression of specific P2X receptors in dystrophin-deficient DMD and mdx muscle. Neuromuscul Disord 2005, 15:225-236.
30. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008, 1783:673-694.
31. Betto R, Senter L, Ceoldo S, Tarricone E, Biral D, Salviati G. Ecto-ATPase activity of alpha-sarcoglycan (adhalin). J Biol Chem 1999, 274:7907-7912.
32. Sandona D, Gastaldello S, Martinello T, Betto R. Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan. Biochem J 2004, 381:105-112.
33. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 2006, 7:762-773.
34. Bodin P, Burnstock G. ATP-stimulated release of ATP by human endothelial cells. J Cardiovasc Pharmacol 1996, 27:872-875.
35. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, Leahy P, Li J, Guo W, Andrade FH. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002, 11:263-272.
36. Yeung D, Kharidia R, Brown SC, Gorecki DC. Enhanced expression of the P2X4 receptor in Duchenne muscular dystrophy correlates with macrophage invasion. Neurobiol Dis 2004, 15:212-220.
37. Ichim TE, Alexandrescu DT, Solano F, Lara F, ReN C, Paris E, Woods EJ, Murphy MP, Dasanu CA, Patel AN, et al. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol 2010, 260:75-82.
38. Yeung D, Zablocki K, Lien CF, Jiang T, Arkle S, Brutkowski W, Brown J, Lochmuller H, Simon J, Barnard EA, et al. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells. FASEB J 2006, 20:610-620.
39. Young CN, Brutkowski W, Lien CF, Arkle S, Lochmüller H, Zablocki K, Górecki DC. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment. J Cell Mol Med 2012, 16:1026-1037.
40. Rawat R, Cohen TV, Ampong B, Francia D, Henriques-Pons A, Hoffman EP, Nagaraju K. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010, 176:2891-2900.
41. Domenighini M, Rappuoli R. Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages. Mol Microbiol 1996, 21:667-674.
42. Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre P, Haag F, Koch-Nolte F. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 2003, 19:571-582.
43. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 2009, 8:1168-1175.
44. Di Virgilio F, Ferrari D, Adinolfi E. P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal 2009, 5:251-256.
45. Araya R, Riquelme MA, Brandan E, Saez JC. The formation of skeletal muscle myotubes requires functional membrane receptors activated by extracellular ATP. Brain Res Brain Res Rev 2004, 47:174-188.
46. Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD. Evidence for functional P2X4/P2X7 heteromeric receptors. Mol Pharmacol 2007, 72:1447-1456.
47. Boumechache M, Masin M, Edwardson JM, Gorecki DC, Murrell-Lagnado R. Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells. J Biol Chem 2009, 284:13446-13454.
48. Casas-Pruneda G, Reyes JP, Perez-Flores G, Perez-Cornejo P, Arreola J. Functional interactions between P2X4 and P2X7 receptors from mouse salivary epithelia. J Physiol 2009, 587:2887-2901.
49. Priel A, Silberberg SD. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol 2004, 123:281-293.
50. Sandonà D, Danieli-Betto D, Germinario E, Biral D, Martinello T, Lioy A, Tarricone E, Gastaldello S, Betto R. The T-tubule membrane ATP-operated P2X4 receptor influences contractility of skeletal muscle. FASEB J 2005, 19:1184-1186.
51. Young CN, Brutkowski W, Lien CF, Arkle S, Lochmuller H, Zablocki K, Gorecki DC. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment. J Cell Mol Med 2012, 16:1026-1037.
52. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S. Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 2005, 332:17-27.
53. Nicke A, Kuan YH, Masin M, Rettinger J, Marquez-Klaka B, Bender O, Gorecki DC, Murrell-Lagnado RD, Soto F. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem 2009, 284:25813-25822.
54. Feng YH, Li X, Wang L, Zhou L, Gorodeski GI. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem 2006, 281:17228-17237.
55. Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, Murrell-Lagnado R. Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts. Br J Pharmacol 2012, 165:978-993.
56. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 2007, 28:465-472.
57. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012, 249:158-175.
58. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet 2011, 20:790-805.
59. Pillon NJ, Bilan PJ, Fink LN, Klip A. Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. Am J Physiol Endocrinol Metab 2013, 304:E453-E465.
60. Coulton GR, Morgan JE, Partridge TA, Sloper JC. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 1988, 14:53-70.
61. Carnwath JW, Shotton DM. Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. J Neurol Sci 1987, 80:39-54.
62. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol 2002, 158:1089-1096.
63. Millay DP, Goonasekera SA, Sargent MA, Maillet M, Aronow BJ, Molkentin JD. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci USA 2009, 106:19023-19028.
64. Kumar A, Khandelwal N, Malya R, Reid MB, Boriek AM. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 2004, 18:102-113.
65. Friedrich O, Both M, Gillis JM, Chamberlain JS, Fink RH. Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice. J Physiol 2004, 555:251-265.
66. Chao CC, Huang CC, Lu DY, Wong KL, Chen YR, Cheng TH, Leung YM. Ca2+ store depletion and endoplasmic reticulum stress are involved in P2X7 receptor-mediated neurotoxicity in differentiated NG108-15 cells. J Cell Biochem 2012, 113:1377-1385.
67. Young CN, Brutkowski W, Lien CF, Arkle S, Lochmuller H, Zablocki K, Gorecki DC. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment. J Cell Mol Med 2012, 16:1026-1037.
68. Yeung D, Zablocki K, Lien CF, Jiang TW, Arkle S, Brutkowski W, Brown J, Lochmuller H, Simon J, Barnard EA, et al. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells. FASEB J 2006, 20:610-620.
69. Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 2001, 15:1169-1180.
70. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J 2004, 18:227-237.
71. Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, Ricordi C, Westendorf AM, Grassi F. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011, 4:ra12.
72. Vergani A, Tezza S, D'Addio F, Fotino C, Liu K, Niewczas M, Bassi R, Molano RD, Kleffel S, Petrelli A, et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 2013, 127:463-475.
73. Henning RH, Duin M, den Hertog A, Nelemans A. Activation of the phospholipase C pathway by ATP is mediated exclusively through nucleotide type P2-purinoceptors in C2C12 myotubes. Br J Pharmacol 1993, 110:747-752.
74. Rigault C, Bernard A, Georges B, Kandel A, Pfutzner E, Le Borgne F, Demarquoy J. Extracellular ATP increases L-carnitine transport and content in C2C12 cells. Pharmacology 2008, 81:246-250.
75. Chan YS, Li Y, Foster W, Horaguchi T, Somogyi G, Fu FH, Huard J. Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 2003, 95:771-780.
76. Iwata Y, Katanosaka Y, Hisamitsu T, Wakabayashi S. Enhanced Na+/H+ exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of P2 receptors. Am J Pathol 2007, 171:1576-1587.
77. Taniguti AP, Pertille A, Matsumura CY, Santo Neto H, Marques MJ. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin: a TGF-beta1 blocker. Muscle Nerve 2011, 43:82-87.
78. Taniguti AP, Matsumura CY, Rodrigues-Simioni L, Santo Neto H, Marques MJ. Suramin affects metalloproteinase-9 activity and increases beta-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx mouse. Muscle Nerve 2012, 46:810-813.
79. Cascabulho CM, Bani Correa C, Cotta-de-Almeida V, Henriques-Pons A. Defective T-lymphocyte migration to muscles in dystrophin-deficient mice. Am J Pathol 2012, 181:593-604.
80. de Oliveira MD, Pereira JA, Taniguti AP, Matsumura CY, Ramos LA, Areas MA, Neto HS. Marques MJ. Muscle Nerve: Suramin attenuates dystrophin-deficient cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy; 2013.
81. Ryten M, Yang SY, Dunn PM, Goldspink G, Burnstock G. Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. FASEB J 2004, 18:1404-1406.
82. Mamedova LK, Wang R, Besada P, Liang BT, Jacobson KA. Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. Pharmacol Res 2008, 58:232-239.